What's holding back value-based pricing deals from moving beyond the pilot phase?
Though Shkreli may soon slip from the public eye, separated from his Twitter account and prohibited from trading securities, pharma communicators must learn from these events.
Trump administration considers outcomes-based approach to lower drug prices; Sanofi to acquire vaccines biotech; Nestle partners with Enterome to develop microbiome-based diagnostics
Harvard Pilgrim signs two outcomes contracts with AstraZeneca; lobbyists fight over drug-pricing proposals; docs say no to adult ADHD screening test
Execs stressed the importance of collaboration, consumer-mindedness.
Novartis, Kaiser, and Qualcomm partner on heart-failure pilot; Novartis and GSK disclose DTC plans; cancer-treatment hype can be negative for patients
A study published in Health Affairs detailed an outcomes-based pilot developed by the drugmaker and Priority Health, a Michigan-based health insurer.
The idea is that each gets some of what it needs. Payers gain some control over cost, and pharma may get to stay on formulary.
But have pharma and payers learned enough from earlier pilots to make modern risk-sharing deals work?
The AMA votes in favor of value-based drug pricing; Amgen says insurers are balking at PCSK9 inhibitor prices; docs aren't focused on prices when prescribing
Gilead CEO talks drug pricing; multiple-sclerosis drugmakers study the overall cost of care; Biden launches national cancer database
Cigna signs value contracts for new cholesterol drugs; Yelp partners with ProPublica for hospital reviews; ad-blocking threat to digital publishers intensifies
The formula's pretty simple: Be sure you can defend your drug's value proposition, without blushing, says BioPharma Alliance's Mike Luby.
Experts say Afrezza's tepid launch may have more to do with value proposition than product positioning.